Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Milena, Kurtinecz"'
Autor:
William Stohl, Milena Kurtinecz, David A Roth, Herbert Struemper, William W Freimuth, Lisa Edwards
Publikováno v:
Lupus Science and Medicine, Vol 9, Iss 1 (2022)
Externí odkaz:
https://doaj.org/article/22de3cc72bf2458aa9500f454d153a48
Autor:
Rafael Perera, Richard Stevens, Jeffrey K Aronson, Amitava Banerjee, Julie Evans, Benjamin G Feakins, Susannah Fleming, Paul Glasziou, Carl Heneghan, FD Richard Hobbs, Louise Jones, Milena Kurtinecz, Daniel S Lasserson, Louise Locock, Julie McLellan, Borislava Mihaylova, Christopher A O’Callaghan, Jason L Oke, Nicola Pidduck, Annette Plüddemann, Nia Roberts, Iryna Schlackow, Brian Shine, Claire L Simons, Clare J Taylor, Kathryn S Taylor, Jan Y Verbakel, Clare Bankhead
Publikováno v:
Programme Grants for Applied Research, Vol 9, Iss 10 (2021)
Background: Long-term monitoring is important in chronic condition management. Despite considerable costs of monitoring, there is no or poor evidence on how, what and when to monitor. The aim of this study was to improve understanding, methods, evide
Externí odkaz:
https://doaj.org/article/41b3c5a60e2444a791bd8cfe2995ced1
Autor:
Kambiz Rahbar, Markus Essler, Kim M. Pabst, Matthias Eiber, Christian la Fougère, Vikas Prasad, Philipp Rassek, Ergela Hasa, Helmut Dittmann, Ralph A. Bundschuh, Wolfgang P. Fendler, Milena Kurtinecz, Anja Schmall, Frank Verholen, Oliver Sartor
Publikováno v:
Journal of Nuclear Medicine. 64:574-578
Autor:
Matthieu Carton, Johanna Peña Del Castillo, Jean-Baptiste Colin, Milena Kurtinecz, Marion Feuilly, Gaëlle Pierron, Pierre Arvis, Soumeya Khadidja Khadir, Monika Sparber-Sauer, Daniel Orbach
Publikováno v:
Future Oncology.
The EPI VITRAKVI study is a retrospective study designed to place the results of the single-arm Phase I/II larotrectinib SCOUT trial into context by comparison with external historical controls. Its primary objective is to compare the time to medical
Autor:
Kambiz, Rahbar, Markus, Essler, Kim M, Pabst, Matthias, Eiber, Christian Peter, la Fougère, Vikas, Prasad, Philipp, Rassek, Ergela, Hasa, Helmut, Dittmann, Ralph A, Bundschuh, Wolfgang Peter, Fendler, Milena, Kurtinecz, Anja, Schmall, Frank, Verholen, Alton O, Sartor
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
The RAdium LUtetium (RALU) study evaluated the feasibility of sequential alpha and beta emitter use in patients with bone-predominant metastatic castration-resistant prostate cancer.This pre-planned, interim, retrospective analysis investigated safet
Autor:
M. Essler, S.S. Santhanam Sundar, S.D. Sabina Dizdarevic, D.S.DanielY. Song, N.A. Neeraj Agarwal, S.G. Saby George, N.S.NealD. Shore, M.K. Milena Kurtinecz, F.V. Frank Verholen, P.S. Per Sandström, O.S. Oliver Sartor, D.G.DanielJ. George
Publikováno v:
60. Jahrestagung der Deutschen Gesellschaft für Nuklearmedizin.
Autor:
Michelle Petri, Helain Landy, Megan E B Clowse, Kim Gemzoe, Munther Khamashta, Milena Kurtinecz, Roger A Levy, Andrew Liu, Rebecca Marino, Paige Meizlik, Jeanne M Pimenta, Kelsey Sumner, Hugh Tilson, Mary Beth Connolly, Keele Wurst, Julia Harris, Holly Quasny, Patricia Juliao, David A Roth
Publikováno v:
Annals of the rheumatic diseases.
ObjectiveDescribe available data on birth defects and pregnancy loss in women with systemic lupus erythematosus (SLE) exposed to belimumab.MethodsData collected from belimumab clinical trials, the Belimumab Pregnancy Registry (BPR), and postmarketing
Autor:
Zahi Touma, Johannes von Kempis, Josefina Cortés-Hernández, Kerry Gairy, Milena Kurtinecz, Christopher E Collins, Andreas Schwarting, Mercedes A. Garcia
Publikováno v:
Rheumatology and Therapy
Introduction The real-world effectiveness of belimumab for systemic lupus erythematosus (SLE) in six countries was evaluated in the OBSErve program. The aim of this post hoc analysis (GSK study 206351) was to pool individual patient OBSErve data to f
Autor:
Kambiz Rahbar, Markus Essler, Matthias Eiber, Christian la Fougère, Vikas Prasad, Wolfgang P. Fendler, Philipp Rassek, Ergela Hasa, Helmut Dittmann, Ralph A. Bundschuh, Kim M. Pabst, Milena Kurtinecz, Per Sandstrom, Frank Verholen, A. Oliver Sartor
5040 Background: 223Ra and 177Lu-PSMA both prolong overall survival (OS) in different mCRPC settings. Previous data from the observational REASSURE (Sartor O, et al. 2021) and WARMTH (Ahmadzadehfar H, et al. 2021) studies suggested the feasibility of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67ce6df1b9034afcd3bdf1c8c2057ed0
Autor:
Kambiz Rahbar, Markus Essler, Matthias Eiber, Christian la Fougère, Vikas Prasad, Kim M. Pabst, Wolfgang Peter Fendler, Philipp Rassek, Ergela Hasa, Helmut Dittmann, Ralph A. Bundschuh, Milena Kurtinecz, Anja Schmall, Frank Verholen, A. Oliver Sartor
Publikováno v:
Journal of Clinical Oncology. 41:73-73
73 Background: 223Ra and 177Lu-PSMA-617 both prolong overall survival (OS) in different mCRPC settings. The observational, retrospective study, RALU, investigated safety and clinical outcomes of sequential 223Ra/177Lu-PSMA therapy in patients (pts) w